Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials.
Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Usmani S, Facon T, Moreau P, Dimopoulos M, Mateos M, Costa L. Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials. Journal Of Clinical Oncology 2020, 38: 8540-8540. DOI: 10.1200/jco.2020.38.15_suppl.8540.Peer-Reviewed Original ResearchHigh-risk cytogeneticsProgression-free survivalPhase III trialsMultiple myelomaR settingIII trialsMature overall survival dataDerSimonian-Laird random-effects modelPhase III randomized trialsRandomized phase III trialFirst-line settingOverall survival dataImproved response ratesRandom-effects modelLog hazard ratioBackbone regimenBackbone regimensHRC patientsRefractory settingPrimary endpointSame regimenFree survivalCytogenetic riskMM patientsRandomized trials